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ABSTRACT 
Background 
The aim of this study was to investigate the association between statin use and 
survival in a population-based colorectal cancer (CRC) cohort and perform an 
updated meta-analysis to quantify the magnitude of any association. 
Methods 
A cohort of 8,391 patients with newly diagnosed Dukes’ A-C CRC (2009-2012) was 
identified from the Scottish Cancer Registry. This cohort was linked to the 
Prescribing Information System and the National Records of Scotland Death 
Records (until January 2015) to identify 1,064 colorectal cancer-specific deaths. 
Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific 
mortality by statin use were calculated using time dependent Cox regression models. 
The systematic review included relevant studies published before January 2016. 
Meta-analysis techniques were used to derive combined HRs for associations 
between statin use and cancer-specific and overall mortality. 
Results 
In the Scottish cohort, statin use before diagnosis (HR=0.84, 95%CI 0.75-0.94), but 
not after (HR=0.90, 95% CI 0.77-1.05), was associated with significantly improved 
cancer-specific mortality.  The systematic review identified 15 relevant studies.  In 
the meta-analysis, there was consistent (I2=0%,heterogeneity P=0.57) evidence of a 
reduction in cancer-specific mortality with statin use before diagnosis in 6 studies 
(n=86,622, pooled HR=0.82, 95% CI 0.79-0.86) but this association was less 
apparent and more heterogeneous (I2=67%,heterogeneity P=0.03) with statin use 
after diagnosis in 4 studies (n=19,152, pooled HR=0.84, 95% CI 0.68-1.04). 
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Conclusion 
In a Scottish CRC cohort and updated meta-analysis there was some evidence that 
statin use was associated with improved survival. However, these associations were 
weak in magnitude and, particularly for post-diagnosis use, varied markedly between 
studies. 
 
KEY WORDS 
Hydroxymethylglutaryl-CoA Reductase Inhibitors; Colorectal Neoplasms; Survival; 
Pharmacoepidemiology; Review, Systematic; Meta-Analysis  
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1. INTRODUCTION 
It is currently estimated that there are 1.4 million incident cases of colorectal cancer 
(CRC) per year worldwide.1 In the United Kingdom (UK), CRC is the second most 
common cause of cancer death with an associated 5-year survival of 50-55%.2,3 
Unfortunately there have been no major advances in the treatment of locally 
advanced CRC since the MOSAIC study (oxaliplatin in addition to standard 
chemotherapy) was published over a decade ago,4 therefore research into novel 
agents or novel use of existing agents is required.5,6 
 
Like aspirin, statins have been identified as potential novel anti-cancer agents that 
are cost-effective and safe to administer.7,8 They inhibit the mevalonate pathway and 
have been shown to have anti-cancer effects in-vitro.9 Our research group previously 
reported an association between both pre- and post-diagnostic statin use and 
improved survival in CRC using observational data.10 However, not all observational 
studies assessing the role of statins in CRC survival support our findings.8,10–19 A 
recent meta-analysis of these studies suggests the associated reduction in cancer-
specific mortality was limited to pre-diagnostic statin users.20 However two other 
meta-analyses conclude that the benefit is observed for both pre- and post-
diagnostic statin users.21,22 Importantly though, none of these meta-analyses capture 
all of the currently available data and they all include hazard ratios for post-
diagnostic statin use from one study13 at risk of immortal time bias.23 To clarify the 
association between post-diagnostic statin use and CRC survival we describe a 
further observational study using an independent population-based UK dataset. We 
also performed an updated systematic review and meta-analysis to include all 
additional data for post-diagnostic use that is not at risk of immortal time bias. 
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2. MATERIALS AND METHODS  
2.1. Cohort study 
2.1.1. Data source 
The study utilised linkages between national datasets from Scotland including the 
Scottish Cancer Registry (SMR06), the Prescribing Information System (available 
from January 2009 to January 2015),24 the General / Acute Inpatient and Day Case 
dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National 
Records of Scotland Death Records. A more detailed description of these data 
resources is described in Supplementary File 1. Linkages between data sources 
were conducted using the Community Health Index number (unique to individuals in 
Scotland).  The Privacy Advisory Committee of the National Health Service (NHS) 
National Services Scotland (NSS) approved the study. 
 
2.1.2. Study population 
A cohort of newly diagnosed CRC patients was identified on the basis of a Scottish 
Cancer Registry recorded primary diagnosis of CRC (comprising ICD codes of the 
colon C18 or rectum C20 including the recto-sigmoid junction C19) between January 
2009 and December 2012. Cohort members with a previous Scottish Cancer 
Registry cancer diagnosis (after January 1999), apart from in situ neoplasms and 
non-melanoma skin cancers, were excluded. 
 
As post-diagnostic medication usage is unlikely to influence survival in cases with 
incident metastatic disease, the analysis of medication use after diagnosis was 
restricted to patients with incident Dukes’ A-C disease.  Deaths were identified from 
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National Records of Scotland with coverage up to 1st January 2015 (or from Scottish 
Cancer Registry death records) with CRC-specific deaths defined as those with 
underlying cause of death ICD code C18, C19, C20, C21 (anus) or C26 (other and 
ill-defined digestive organs). Deaths in the first year after CRC diagnosis were 
removed, this restriction reduces the likelihood of including patients who were not 
recurrence-free at exposure.25 Patients were therefore followed from one year after 
CRC diagnosis to death, the date they left Scotland or 1st January 2015, whichever 
occurred first. 
 
2.1.3. Exposure data  
Statins dispensed in the community (identified from the Prescribing Information 
System) consisted of all medications in the Statins section of the British National 
Formulary (Section 2.12).26 A quantity of 28 tablets was assumed for the less than 
0.1% of prescriptions where quantity was deemed incorrect. Daily defined doses 
(DDD) in each prescription were calculated by multiplying the quantity by strength (in 
mg) and dividing by the World Health Organization defined DDD (in mg) for 
individual statins as defined by the).27 Statin use was investigated as a time-varying 
covariate (patients were initially considered non-users and then users after a lag of 6 
months after their first statin prescription).23 The use of a lag is recommended25 and 
in this study prescriptions in the 6 month period prior to death were not considered 
as these may reflect end of life treatment (in sensitivity analyses the duration of this 
lag was varied). Dose-response analyses were conducted with individuals 
considered non-users prior to 6 months after first use, a short term user between 6 
months after first use and 6 months after the 12th prescription (or 365 DDDs) and a 
longer term user after this time. 
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2.1.4. Covariates 
Data available from the Scottish Cancer Registry included Dukes’ stage, histological 
grade and surgery, chemotherapy and radiotherapy in the six months after 
diagnosis.  Comorbidities that contribute to the Charlson index were determined prior 
to diagnosis based upon ICD10 diagnosis codes, as described previously,28 in 
Scottish hospital inpatient (SMR01) and outpatient data (SMR00). A deprivation 
measure was determined using the 2009 Scottish Index of Multiple Deprivation 
based upon postcode of residence.29 Low-dose aspirin use was determined from 
dispensing records. 
 
2.1.5. Statistical analysis 
In the main analysis, time-dependent Cox regression models were used to calculate 
hazard ratios (HRs) for CRC-specific death and 95% confidence intervals (95% CI) 
for post-diagnostic statin users compared with non-users using a time-varying 
covariate as described previously. Deaths from other causes were censored in 
cancer-specific analyses. Adjusted analyses were conducted including the following 
potential confounders: sex, age, year of diagnosis, deprivation (in fifths), grade, site 
(colon or rectal), Dukes’ stage, surgery (within 6 months of diagnosis), radiotherapy 
(within 6 months of diagnosis), chemotherapy (within 6 months of diagnosis), 
comorbidities (dichotomised as absent or present prior to diagnosis, including acute 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral 
vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal 
disease) and aspirin usage (as time-varying covariate).  Other commonly prescribed 
medications with potential anti-cancer effects (metformin, drugs affecting the renin-
angiotensin system and beta-blockers) were not included in the final models, as they 
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did not alter the hazard ratio estimates. Analyses were conducted by number of 
prescriptions, number of DDDs and type of statin and repeated for all-cause 
mortality. Subgroup analyses were conducted by site (colon or rectal), stage (I-III), 
treatment (surgery alone versus surgery and adjuvant therapy) and finally for post-
diagnostic statin users, de novo versus pre- and post-diagnostic statin use.  
 
Sensitivity analysis was conducted by increasing the lag to 1 year. A simplified 
analysis was also performed using Cox regression to compare statin users to non-
users in the first year after CRC diagnosis in individuals living more than 1 year after 
diagnosis; this controls for immortal time bias without requiring time-varying 
covariates.30 Finally, an analysis was conducted based upon statin prescriptions in 
the year prior to diagnosis (excluding patients diagnosed in 2009 for whom a full year 
of prescription records prior to diagnosis may not be available), not excluding deaths 
in the first year after diagnosis and including all CRC patients regardless of Dukes’ 
stage. To avoid overadjustment this analysis did not adjust for stage and grade, or 
restrict the cohort to Dukes’ stage A to C disease, because these variables could be 
on the causal pathway for the association between pre-diagnostic statin use and 
CRC–specific mortality.31,32 For comparison between studies a fully adjusted model 
was also included. Finally, as the prevalence of commonly prescribed medications 
may increase in the period before cancer diagnosis an alternative definition of pre-
diagnostic statin use in the 12-month period one to two years prior to diagnosis was 
also assessed (this definition requires the exclusion of patients diagnosed in 2009 
and 2010). 
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2.2. Systematic review and meta-analysis 
2.2.1. Search strategy 
The review protocol was undertaken according to the principles recommended by 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
33 and Meta-analysis of Observational Studies in Epidemiology (MOOSE) group34 
statements. It was registered with the PROSPERO international prospective register 
of systematic reviews (http://www.crd.york.ac.uk/PROSPERO, registration number 
CRD42015017915). A systematic search of the literature was performed using 
Medline (US National Library of Medicine, Bethesda, Maryland, USA), Embase 
(Reed Elselvier PLC, Amsterdam, Netherlands) and Web of Science (Thompson 
Reuters, New York, USA). The search encompassed all studies published from 
database inception to January 12 2016. Keywords and Medical Subject Headings 
(MeSH) relating to statins and CRC were used following the strategies detailed in 
Supplementary File 1. References of all eligible studies were also searched for 
additional relevant studies. 
 
2.2.2. Study selection and eligibility criteria 
Two independent reviewers (R.T.G. and H.G.C.) screened all titles and abstracts to 
identify eligible studies. Full-text manuscripts were reviewed in cases where the title 
and abstract provided insufficient information to determine eligibility. Disagreements 
were resolved after discussion with a third party (L.J.M.). Studies were considered 
for inclusion if (i) they identified a cohort of CRC patients in which exposure to statin 
treatment was measured and recorded and (ii) they determined an estimate of 
progression of CRC (i.e. overall, cancer-specific, recurrence-free, progression-free or 
disease free survival) in a statin user group compared with non-users using 
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measures of effect or association (HR, relative risk (RR) or odds ratio (OR)) and 
corresponding 95% CI, or enough information to allow these to be calculated. 
Abstracts and non-English language articles were included if they met the criteria 
above. Authors were contacted for further information when required. Results from 
the current cohort study were also included in the final pooled analyses. 
 
2.2.3. Data extraction and study quality assessment 
Standardised data extraction forms were used to collect information on the variables 
listed in Supplementary File 1 (R.T.G). When the information was not clear this was 
discussed with a second investigator (H.G.C). The methodological quality of the 
studies included in the meta-analysis was assessed (R.T.G.) using the Newcastle-
Ottawa scale for cohort studies35 and the Cochrane risk of bias tool for randomised 
controlled trials (RCTs).36 When the judgement of the domain was not immediately 
clear it was discussed with a second investigator (H.G.C. or C.R.C.). 
 
2.2.4. Statistical analysis 
The statistical analysis was conducted using Review Manager (RevMan [Computer 
program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). A random effects model was used to produce pooled estimates 
from the fully adjusted HRs and CIs of included studies. If these were not available 
estimates of the HR and standard error were produced using the indirect method 
proposed by Parmar et al.37 Meta-analyses were conducted separately on statin use 
before and after diagnosis. Study outcomes for post-diagnostic statin use deemed to 
be at risk of immortal time bias, where the exposed group acquire follow-up from a 
fixed time point (such as diagnosis date) but do not actually commence statin 
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therapy to later in their follow-up, were not included in the pooled analyses.23 
Between-study heterogeneity was assessed using the Cochrane Q statistic (χ2 test) 
and the I2 statistic.38 Funnel plot asymmetry was visually assessed to determine the 
potential for publication bias. A number of a priori subgroup analyses were 
considered including tumour location (colon versus rectum), sex, age (>65 years 
versus ≤65 years) and disease stage. Finally, sensitivity analyses were performed by 
systematically removing each individual study in order to assess its effect on the 
pooled result estimates and accompanying heterogeneity. 
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3. RESULTS 
3.3. Cohort study 
3.3.1. Patient cohort  
A total of 8,391 incident Dukes’ A to C CRC cases met the inclusion criteria 
(Supplementary Figure 1), in which there was, on average, 2.4 years of  exposure-
related follow-up starting one year after diagnosis (sd=1.3, minimum=0, maximum=5 
years). Patient characteristics by statin use are shown in Table 1. Statin users were 
more likely to be older and male. Stage and grade were generally similar by statin 
use, but a smaller proportion of statin users compared with statin non-users had 
Dukes’ C disease (post-diagnostic use 32.5% versus 36.2% respectively). Statin 
users were more likely to have comorbidities (particularly cerebrovascular disease, 
diabetes and myocardial infarction) and use concomitant aspirin, but a smaller 
proportion received adjuvant chemotherapy.  
 
3.3.2. Association between post-diagnostic statin use and survival 
Overall, there was no statistically significant reduction in CRC-specific mortality when 
post-diagnostic statin users were compared with statin non-users (Table 2). 
Similarly, there was no evidence of a dose-response association when exposure was 
investigated using DDDs. The absence of an association with CRC-specific survival 
persisted when simvastatin was assessed and after adjustment for potential 
confounders. Similar results were observed for adjusted all-cause mortality in terms 
of marginal non-significant reductions in mortality.  
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3.3.3. Sensitivity / subgroup analyses 
Sensitivity / subgroup analyses are shown in Table 3. Stratifying by tumour location, 
overall mortality was reduced for post-diagnostic statin users compared to statin non-
users in patients with colon cancer (HR=0.85, 95% CI 0.74 to 0.98). However, this 
subgroup benefit was less apparent for CRC-specific mortality (HR=0.88, 95% CI 
0.74 to 1.06). There was some evidence of reduced CRC-specific mortality for statin 
users compared to non-users when the analysis was restricted to stage II tumours 
but this was only of marginal statistical significance (HR=0.75, 95% CI 0.56 to 1.00, 
Supplementary Table 1). There was no evidence of a differential association when 
cases were stratified by treatment with surgery alone compared to those receiving 
additional adjuvant therapies (Supplementary Table 1). Increasing the lag period to 
one year did not alter the results for post-diagnostic statin use and CRC-specific 
mortality (adjusted HR=0.93, 95% CI 0.79 to 1.08). Repeating the analysis using a 
simplified 1 year analysis also did not demonstrate a survival benefit for post-
diagnostic statin use (Table 3). When post-diagnostic statin use versus non-use was 
stratified by de novo compared to prior statin use, de novo post-diagnostic statin 
users had a more pronounced reduction in cancer-specific and overall mortality. 
However, the interactions for CRC-specific and overall mortality (P for 
interaction=0.34 and 0.35, respectively) were not significant. Finally, in contrast to 
the non-significant association observed for post-diagnostic statin use, CRC-specific 
mortality and overall mortality were significantly improved by 16% (HR=0.84, 95%CI 
0.75 to 0.94) and 11% (HR=0.89, 95% CI 0.80 to 0.98) respectively comparing pre-
diagnostic statin users (in the year prior to diagnosis) with statin non-users. These 
associations were not significantly altered when the definition of pre-diagnostic use 
16 
 
was changed to include any use in the one year period one to two years prior to 
diagnosis (results not shown). 
 
3.4. Systematic review and meta-analysis 
3.4.1. Search results and study characteristics 
Fifteen studies were deemed eligible for inclusion in the final review after screening 
1192 titles and abstracts (Figure 1). There was one RCT,39 six prospective 
population-based studies,8,10,11,16,18,40 two cohorts within RCTs,12,15 one prospective 
cohort within a population-based case-control study13 and five retrospective hospital-
based cohorts(Table 4).14,17,19,41,42 Seven studies assessed stage I-IV 
disease,11,13,14,17–19,40 three assessed stage I-III disease,10,16,41 two stage III disease 
only,15,42 two stage IV disease only,12,39 and one did not report stage.8 Two studies 
reported outcomes for only rectal cancer patients,14,41 one study consisted of only 
male subjects17 while another related to patients with diabetes mellitus only.18 Eleven 
studies reported outcomes for post-diagnostic statin use10–15,18,19,39,40,42 and six 
reported pre-diagnostic statin use.8,10,13,16,17,41 The methodological quality of these 15 
studies (n=14 observational, n=1 RCT) was evaluated using relevant risk of bias 
tools (Supplementary Table 2 and 3). In addition to these studies, we also included 
the results from our own population-based cohort study (described above).  
 
3.4.2. Post-diagnostic statin use 
Four studies with 19,152 patients reported CRC-specific mortality in post-diagnostic 
statin users compared to statin non-users but only two of them, the current study and 
Cardwell et al,10 assessed statin use as a time-varying covariate. The pooled HR 
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was 0.84 (95% CI 0.68 to 1.04) with evidence of significant heterogeneity 
(heterogeneity P=0.03; I²=67%) (Figure 2A). Removing the study by Cardwell et al.10 
in sensitivity analysis reduced this statistical heterogeneity but moved the 
association closer to null (Supplementary Table 4).  
 
Twelve studies reported overall mortality in relation to post-diagnostic statin use but 
the HR reported by Lakha et al.13 was excluded as it has previously been identified 
as being at risk of immortal time bias.10,20  Eleven studies (21,030 patients) were 
subsequently included in the pooled analysis for which the HR was 0.84 (95% CI 
0.73 to 0.98). Again, there was a high level of statistical heterogeneity (heterogeneity 
P=0.0004; I²=69%) (Figure 2B). There was also methodological heterogeneity 
amongst the studies included in this analysis. Only four studies (the current study, 
Cardwell et al.,10 Voorneveld et al.40 and Zanders et al.18) assessed post-diagnostic 
statin use as a time-varying covariate, one considered a diabetic cohort only18 and a 
further two assessed the role of statins in stage IV disease only.12,39 Removing 
individual studies in sensitivity analysis did not markedly alter the result or 
associated heterogeneity for overall mortality and post-diagnostic statin use 
(Supplementary Table 4). 
 
3.4.3. Pre-diagnostic statin use 
Six studies with 86,622 patients reported CRC-specific mortality in pre-diagnostic 
statin users compared to statin non-users. The pooled HR was 0.82 (95% CI 0.79 to 
0.86) with no evidence of heterogeneity (heterogeneity P=0.57; I²=0%) (Figure 3A). 
Statin exposure was determined through linkage to dispensing or prescribing 
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databases in all of the studies included in this pooled analysis and four of the six 
were large population-based studies.  
 
Six studies (44,026 patients) also reported overall mortality in relation to pre-
diagnostic statin use. The pooled HR for overall mortality was 0.85 (95% CI 0.76 to 
0.95) although there was evidence of significant heterogeneity in this analysis 
(heterogeneity P=0.0009; I²=76%) (Figure 3B). There was also greater 
methodological heterogeneity associated with this analysis as one study41 relied on 
medical record review rather than data linkage and only three were prospective 
population-based cohorts (current study, Cardwell et al.10 and Shao et al.16). The 
heterogeneity associated with the pooled analysis for pre-diagnostic statin use and 
overall mortality reduced from 76% to 48% when the only study associated with 
increased mortality was removed (Supplementary Table 4). Removing the other 
studies individually had no significant impact on the result or associated 
heterogeneity. 
 
3.4.4. Subgroup analyses and publication bias 
Survival estimates stratified by age, sex, stage and tumour location were not 
consistently reported therefore the planned subgroup analysis could not be reliably 
performed. Funnel plots showed no evidence of asymmetry for cancer-specific or 
overall mortality in pre- or post-diagnostic statin use (Supplementary Figure 2).  
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4. DISCUSSION 
In a large Scottish cohort of CRC patients we identified some evidence of an inverse 
association between CRC-specific mortality and statin use before diagnosis but less 
evidence of an association with statin use after diagnosis. In particular, while de 
novo post-diagnostic statin use was associated with reduced cancer-specific 
mortality in a subgroup analysis, this association was based on relatively few events 
and the interaction term for this stratification was not statistically significant. An 
updated systematic review and meta-analysis was subsequently performed which 
demonstrated an association with relatively small reductions in cancer-specific and 
all-cause mortality with statin use before and after diagnosis. However, these 
associations generally lacked consistency and the association between cancer-
specific mortality and post-diagnostic statin use did not reach statistical significance.  
 
We previously reported an association between improved survival outcomes and 
post-diagnostic statin use in a cohort of 7,657 patients within the UK National Cancer 
Data Repository.10 However, despite using very similar methodology, the association 
with reduced mortality was smaller and non-significant in this current Scottish cohort 
of 8,391 patients. In addition to the possibility of differences in unknown lifestyle 
factors, one potential explanation for the failure to demonstrate a significant inverse 
association between post-diagnostic statin use and mortality in the current study is 
that it is more contemporaneous (2009-2012 versus 1998-2009). In more recent 
years important changes in the detection and management of CRC occurred 
including the full implementation of the bowel cancer screening programme in 
Scotland in 200943 and the availability of oxaliplatin-based adjuvant chemotherapy 
from 2006.44 It is possible that undergoing screening (with the potential to have an 
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earlier stage tumour) or receiving oxaliplatin-based chemotherapy could be 
associated with statin use. Therefore, potential confounding by these factors could 
contribute to the different findings observed in our studies.  
 
The results of other studies assessing post-diagnostic statin use are similarly 
heterogeneous (I² 67%-69%) and may represent the absence of a standardised 
methodological approach. The numerous different methods could explain some of 
this heterogeneity. For example, the use of patient self-reporting measures to 
determine statin use potentially introduces recall bias and limiting the study 
population to stage IV disease or diabetic patients reduces external validity. Finally, 
only four studies reported cancer-specific mortality in post-diagnostic statin users 
compared to 11 studies reporting overall mortality. The inverse association with 
survival outcomes and post-diagnostic statin use was only statistically significant for 
overall mortality in the subsequent meta-analysis. However, as this could reflect non-
cancer related mortality, further studies assessing cancer-specific mortality are 
required.  
 
In comparison to the results for post-diagnostic statin use, the significant association 
between improved survival outcomes and pre-diagnostic statin use observed in the 
UK National Cancer Data Repository cohort10 persisted in the Scottish cohort study, 
albeit the magnitude of the effect was smaller. The subsequent pooled analysis 
demonstrated pre-diagnostic statin use was associated with an 18% reduction in 
cancer-specific mortality. The absence of statistical heterogeneity in this analysis 
contrasts with the other pooled analyses and could represent a more homogeneous 
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methodological approach. In this case, the majority of studies used large-scale 
population-based designs and utilised prescribing or dispensing database 
information. Overall there were also four times as many patients in the pre- 
compared to post-diagnostic pooled analysis for cancer-specific mortality. However, 
the consistent association observed for pre-diagnostic users is perhaps less clinically 
useful, as it is difficult to intervene before diagnosis, whereas an association with 
post-diagnostic use could represent the potential for use as a novel adjuvant agent.  
 
It remains unclear if the molecular phenotype of CRC developing in pre-diagnostic 
statin users is different to statin non-users and whether this difference conveys a 
survival benefit. While no benefit for statin use was identified when survival analyses 
were stratified by KRAS status11,15 or MSI,11 the field of personalised cancer 
treatment is evolving and further studies should consider the molecular profile of the 
tumour. Additional molecular pathological epidemiology studies assessing CRC risk 
and progression could provide further insights into the anti-cancer effect of statins 
and identify potential biomarkers to tailor treatment.45 In particular TP53 mutations,46 
immunohistochemical expression of hydroxymethylglutaryl-CoA reductase47,48 and 
single nucleotide polymorphisms in the genes which encode proteins involved in 
statin metabolism48 have been identified as potential biomarkers to differentiate 
potentially statin sensitive tumours and warrant further study.  
 
The strengths of the Scottish cohort study include its large population-based design 
and use of dispensing information with detailed information on the type, timing and 
dose of statins being used. One of the main limitations is that this is an observational 
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study and there is the potential for residual confounding for which we could not 
control. The follow-up period was also relatively short (average 3.4 years from 
diagnosis with 2.4 years of follow-up) and may not be sufficient to fully assess the 
potential beneficial effect of statins. However, three studies included in the review 
have similar follow-up periods (average/median 3.4-3.8 years),11,18,40 two of which 
demonstrated a survival benefit for post-diagnostic statin use and overall 
mortality.18,40 While dispensing information is more robust than prescribing 
information, compliance cannot be confirmed. Cause of death can also be 
misclassified when relying on data from national statistics records.8 Healthy-user 
bias49 could be responsible for the observed improvement in survival for pre-
diagnostic users but co-morbidities were actually higher in statin users. Finally, statin 
users had a smaller proportion of Dukes’ C cancers but the adjusted analyses should 
correct for this difference.  
 
Compared to prior systematic reviews and meta-analyses,20–22 the present updated 
one benefits from the ability to include data from the Scottish cohort study and at 
least five further studies.19,39–42 The three previous reviews20–22 also incorporated 
results from one study13 identified as being at risk of immortal time bias,10,20 whereas 
it was excluded from our pooled analysis. In addition, the review by Zhong et al.20 
excluded the estimate reported by Nielsen et al.8 (n=43,487 patients) for colon 
cancer-specific mortality and pre-diagnostic statin use despite identifying the study. 
The review by Ling et al.21 included the HR from both the nationwide cohort study 
and nested matched study reported by Nielsen et al.8 adding inappropriate extra 
weight to this study as individuals were counted twice. Finally Ling et al.21 and Cai et 
al.22 have misclassified the HR for overall mortality reported by Siddiqui et al.17 as 
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cancer-specific mortality.  Therefore, we believe our review adds improved rigour to 
prior systematic evaluations of this topic. 
 
In summary, combining the results of this cohort study and the updated systematic 
review and meta-analysis suggests that statin use appears to be associated with 
reduced mortality in CRC. However the magnitude of the effect is weak and the 
association may not be causal. The association also varies markedly between 
studies for statin use after diagnosis, the only time point at which clinical intervention 
is possible. Importantly, the only RCT assessing adjuvant statin therapy after surgery 
for early stage colon cancer (NCT01011478)50 has been terminated due to poor 
accrual (predominantly due to limited numbers of statin-naïve patients - personal 
communication, NSABP, 2015). To inform the decision to conduct future trials, 
further observational studies reporting cancer-specific survival outcomes are 
therefore required to clarify the association between post-diagnostic statin use and 
CRC-specific survival.  
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Table 1.  Characteristics of colorectal cancer patients by post-diagnostic statin 
use 
 
Statin use in first year after 
cancer diagnosis* 
 
Yes  No 
 n % n % 
Age  
     <50 20 0.6 425 8.1 
  50-59 248 7.9 996 19.0 
  60-69 927 29.6 1,632 31.1 
  70-79 1,348 43.0 1,462 27.8 
  ≥ 80 594 18.9 739 14.1 
Men 1,913 61.0 2,761 52.6 
Deprivation (fifth)     
  1 (most deprived) 632 20.1 854 16.3 
  2 711 22.7 1,058 20.1 
  3 618 19.7 1,074 20.4 
  4 641 20.4 1,132 21.5 
  5 (least deprived) 535 17.1 1,135 21.6 
Colon 2204 70.3 3,516 66.9 
Rectum† 933 29.7 1,738 33.1 
Dukes’ stage     
  A 931 29.7 1,349 25.7 
  B 1,187 37.8 2,004 38.1 
  C 1,019 32.5 1,901 36.2 
Grade     
  Well differentiated 119 3.8 166 3.2 
  Moderately differentiated 2,450 78.1 3,992 76.0 
  Poorly differentiated 432 13.8 851 16.2 
  Missing 136 4.3 245 4.7 
Treatment (within 6 months)     
  Surgery 2,972 94.7 4,956 94.3 
  Radiotherapy 258 8.2 613 11.7 
  Chemotherapy 693 22.1 1,946 37.0 
Comorbidity before cancer diagnosis     
   Acute myocardial infarction 352 11.2 51 1.0 
   Congestive heart failure 166 5.3 63 1.2 
   Peripheral vascular disease 181 5.8 44 0.8 
   Cerebral vascular accident 244 7.8 59 1.1 
   Pulmonary disease 277 8.8 313 6.0 
   Peptic ulcer  101 3.2 109 2.1 
   Liver disease 7 0.2 24 0.5 
   Diabetes 467 14.9 108 2.1 
   Renal disease 109 3.5 80 1.5 
Aspirin use  1,647a 52.5a 503a 9.6a 
*Restricted to patients who survived at least one year after diagnosis 
†Includes recto sigmoid junction  
a – Refers to aspirin use in the year after diagnosis 
Abbreviation: n – number. 
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Table 2. Association between statin use after diagnosis and cancer-specific and all-cause mortality in patients with 
colorectal cancer. 
 
Mortality Patients Person 
Years 
Unadjusted HR 
(95% CI) 
P Adjusted1 HR 
(95%CI) 
P 
Cancer-specific mortality 
Statin non-user 639 4,766 13,224 1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 425 3,625 8,910 1.01 (0.89, 1.14) 0.89 0.90 (0.77, 1.05) 0.17 
        
1-12 prescriptions vs. 
non-user 
257 1,199 4,927 1.00 (0.86, 1.16) 0.98 0.89 (0.75, 1.06) 0.19 
≥ 12 prescriptions vs. 
non-user 
168 2,426 3,983 1.03 (0.86, 1.23) 0.78 0.91 (0.74, 1.12) 0.39 
        
1 to 365 DDDs  vs. 
non-user 
271 1,470 5,196 1.02 (0.89, 1.18) 0.75 0.90 (0.77, 1.07) 0.23 
≥ 365 DDDs  vs. non-
user 
154 2,155 3,714 0.98 (0.82, 1.18) 0.85 0.90 (0.72, 1.10) 0.29 
        
Simvastatin non-user 761 5,789 15,799 1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 303 2,602 6,335 1.02 (0.89, 1.17) 0.76 0.96 (0.83, 1.12) 0.63 
        
Overall mortality 
Statin non-user 906 4,766 13,224 1.00 (ref. cat.)  1.00 (ref. cat.)  
Statin user 729 3,625 8,910 1.20 (1.09, 1.33) <0.001 0.90 (0.80, 1.02) 0.09 
        
1-12 prescriptions  vs. 
non-user 
405 1,199 4,927 1.16 (1.03, 1.30) 0.02 0.89 (0.78, 1.02) 0.11 
≥ 12 prescriptions  vs. 
non-user 
324 2,426 3,983 1.27 (1.11, 1.45) 0.001 0.91 (0.78, 1.07) 0.25 
        
1 to 365 DDDs  vs. 
non-user 
436 1,470 5,196 1.21 (1.07, 1.35) 0.001 0.91 (0.80, 1.04) 0.18 
≥ 365 DDDs  vs. non-
user 
293 2,155 3,714 1.21 (1.05, 1.38) 0.007 0.88 (0.75, 1.03) 0.11 
        
Simvastatin non-user 1,126 5,789 15,799 1.00 (ref. cat.)  1.00 (ref. cat.)  
Simvastatin user 509 2,602 6,335 1.14 (1.02, 1.26) 0.02 0.94 (0.83, 1.05) 0.26 
1Model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment 
within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary 
disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (as time-varying covariate). 
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Table 3. Sensitivity analysis of association between statin use and cancer-specific and all-cause mortality in patients with colorectal cancer.  
 Medication User   Medication Non-user      
 
Cancer \ All 
Mortality 
Patients Person 
Years 
Cancer \ All 
Mortality 
Patients Person 
Years 
Unadjusted HR 
(95% CI) 
P Adjusted HR 
(95%CI) 
P 
Cancer-specific mortality 
Subgroup analyses:  Statin users versus non-users1         
Colon cancer 300 3,132 6,238 442 3,309 8,766 0.99 (0.85, 1.14) 0.88 0.88 (0.74, 1.06) 0.17 
Rectal cancer† 125 1,397 2,673 197 1,618 4,458 1.06 (0.85, 1.32) 0.62 0.98 (0.74, 1.30) 0.88 
Use in first year after diagnosis           
Statin user vs. non-user2 408 3,137 8,257 656 5,254 13,877 1.04 (0.92, 1.18) 0.50 0.95 (0.81, 1.11) 0.51 
Simvastatin vs. versus non-user2 288 2,149 5,655 776 6,242 16,480 1.08 (0.94, 1.24) 0.26 1.03 (0.89, 1.20) 0.70 
 Post-diagnostic use stratified by pre-diagnostic use1          
Statin user (pre- plus post-diagnostic) vs. 
non-user (excludes 2009 cases) 255 2223 4952 19 116 304 0.83 (0.52, 1.32) 0.43 0.95 (0.59, 1.53) 0.83 
Statin user (de-novo post-diagnostic) vs. 
non-user (excludes 2009 cases) 24 444 698 434 3543 8317 0.69 (0.46, 1.05) 0.08 0.64 (0.42 ,0.99) 0.05 
Use in year before CRC diagnosis           
Statin user vs. non-user3 1,418 3,967 9,297 2,237 6,441 15,815 1.06 (1.00, 1.14) 0.06 0.83 (0.77, 0.90) <0.001 
Statin user vs. non-user (fully adjusted)4        0.84 (0.75, 0.94) 0.002 
Simvastatin user vs. non-user3 1,006 2,755 6,373 2,649 7,653 18,738 1.10 (1.02, 1.18) 0.01 0.92 (0.85, 1.00) 0.05 
Simvastatin vs. non –user (fully adjusted)4        0.95 (0.85, 1.06) 0.33 
All-cause mortality 
Subgroup analyses:  Statin users versus non-users1         
Colon cancer 516 3,132 6,238 636 3,309 8,766 1.16 (1.03, 1.30) 0.02 0.85 (0.74, 0.98) 0.03 
Rectal cancer† 213 1,397 2,673 270 1,618 4,458 1.31 (1.09, 1.57) 0.003 1.03 (0.82, 1.29) 0.82 
Use in first year after diagnosis           
Statin user vs. non-user2 691 3,137 8,257 944 5,254 13,877 1.23 (1.11, 1.36) <0.001 0.93 (0.82, 1.05) 0.24 
Simvastatin user vs.non-user2 474 2,149 5,655 1,161 6,242 16,480 1.19 (1.07, 1.32) 0.001 0.98 (0.87, 1.10) 0.74 
 Post-diagnostic use stratified by pre-diagnostic use1          
Statin user (pre- plus post-diagnostic) vs. non-
user (excludes 2009 cases) 422 2223 4952 31 116 304 0.82 (0.57, 1.18) 0.29 0.92 (0.62, 1.36) 0.67 
Statin user (de-novo post-diagnostic) vs. non-
user (excludes 2009 cases) 42 444 698 587 3543 8317 0.87 (0.63, 1.19) 0.38 0.68 (0.48, 0.96) 0.03 
Use in year before CRC diagnosis           
Statin user vs.non-user3 1,907 3,967 9,297 2,716 6,441 15,815 1.18 (1.11, 1.25) <0.001 0.86 (0.80, 0.92) <0.001 
Statin user vs. non-user (fully adjusted)4        0.89 (0.80, 0.98) 0.02 
Simvastatin user vs. non-user3 1,336 2,755 6,373 3,287 7,653 18,738 1.18 (1.11, 1.26) <0.001 0.93 (0.87, 1.00) 0.04 
Simvastatin vs. non-user (fully adjusted)4        0.97 (0.88, 1.06) 0.47 
35 
 
†Includes rectosigmoid junction 
1Based upon main time-varying covariate analysis adjusted model containing age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, 
surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal 
disease) and aspirin use (as time-varying covariate). 
2Model contains age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months (radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute 
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, liver disease, diabetes, renal disease) and aspirin use (in first year after diagnosis). 
3Excluding patients diagnosed in 2009 (who do not have complete prescription records for year before diagnosis) but not excluding patients who die within 1 year of diagnosis; adjusted model contains age, sex, year of 
diagnosis, deprivation, site (colon or rectum), comorbidities (prior to diagnosis, including acute myocardial infarction, congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic 
ulcer, liver disease, diabetes, renal disease) and aspirin use (in year prior to diagnosis). 
4Adjusting for variables in (3) but additionally adjusting for stage, grade and cancer treatment within 6 months (radiotherapy, chemotherapy, surgery). 
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Table 4. Baseline characteristics of included studies investigating statin use and survival outcomes in colorectal cancer. 
First Author (year) 
Country 
Study design  
(Exposure Ascertainment) 
Study Period 
(Follow-up) 
No. of 
Patients 
Tumour 
Location Stage 
Statin 
Use Outcome Adjusted Variables 
Lim (2015)39 
Korea 
RCT 
(N/A) 
2010-2013 
(NR) 
269 CRC IV Post OM¶ Unadjusted hazard ratio provided by the study authors through personal communication. 
Current study 
Scotland 
Prospective population-
based cohort  
(Dispensing database) 
2009-2012 
(Censored 2015, 
mean 3.4 years) 
8391 CRC I-III Post CSM  
&  
OM 
Age, sex, year of diagnosis, deprivation, site (colon or rectum), stage, grade, cancer treatment within 6 months 
(radiotherapy, chemotherapy, surgery), comorbidities (prior to diagnosis, including acute myocardial infarction, 
congestive heart failure, peripheral vascular disease, cerebral vascular accident, pulmonary disease, peptic ulcer, 
liver disease, diabetes, renal disease) and aspirin use (as time-varying covariate). 
Cardwell (2014)10 
England 
Prospective population-
based cohort  
(Prescribing database) 
1998-2009          
(Censored 2012, 
mean 5 years) 
7657 CRC I-III Pre  
& 
Post† 
CSM  
&  
OM 
Year of diagnosis, age at diagnosis, sex, stage, surgery within 6 months, radiotherapy within 6 months, 
chemotherapy within 6 months, site, comorbidities,  low-dose aspirin, ACEIs, and metformin use after diagnosis as 
time-varying covariates, grade, deprivation, and smoking before diagnosis. Post- but not pre-diagnostic analyses 
adjusted for stage and grade as potentially on causal pathway. 
Hoffmeister (2015)11  
Germany 
Prospective population-
based cohort  
(Patient reported) 
2003-2009      
 (Median 3.4 
years) 
2697 CRC I-IV Post‡ CSM  
&  
OM 
Age at diagnosis, sex, stage, site, surgery, neoadjuvant treatment, chemotherapy, radiotherapy, BMI, lifetime pack-
years of active smoking, physical activity, diabetes, ever regular use of NSAIDs including aspirin, ever use of HRT 
among women, previous large bowel endoscopy, hypercholesterolemia, myocardial infarction, stroke, heart failure, 
participation in general health check-ups, late entry into the study, and time-dependent effect chemotherapy. 
Nielsen (2012)8  
Denmark 
Prospective population-
based cohort 
(Dispensing database) 
1995-2007  
(Censored 2009) 
43487 Colon NR Pre CSM Age at diagnosis, stage, chemotherapy, radiotherapy, cardiovascular disease, diabetes mellitus, year of birth, sex, 
descent, education, and size of residential area. **Tumour staging only available for 3 years (2004-2007). 
Shao (2015)16 
Taiwan 
Prospective population-
based cohort  
(Insurance database) 
2004-2008      
(Censored 2011, 
median 4.2 years) 
17115 CRC I-III Pre CSM  
&  
OM 
Age, sex, tumour stage, adjuvant therapy and a propensity score for statin use modelled on age, sex, year of 
diagnosis, physician visits and hospitalisation 1 year prior to diagnosis, aspirin, NSAIDs, insulin, oral anti-diabetic 
medication, ACEIs, ARBs and comorbidities. 
Zanders (2015)18  
Netherlands 
Prospective population-
based cohort  
(Dispensing database) 
1998-2011 
(Censored 2011, 
mean 3.4 years) 
1043 CRC I-IV Post† OM¶ Metformin, sulfonylurea derivatives, insulin, other diabetes medication, statins and aspirin after diagnosis as time-
dependent ever-never terms, the use of these drugs before diagnosis as a dichotomised variable, and the time-
fixed variables: sex, age at CRC diagnosis, calendar year of CRC diagnosis, type of CRC, stage and administration 
of surgery, radiotherapy and/or chemotherapy. 
Voorneveld (2015)40 
Netherlands 
Prospective population-
based cohort  
(Dispensing database) 
1998-2007 
(Censored 2012, 
median 3.8 years) 
999 Colon I-IV Post† OM¶ Unadjusted hazard ratio estimated using Parmar’s method based on the log rank test provided through personal 
communication. 
Krens (2014)12 
Netherlands 
Prospective cohort within 
RCT (Patient reported) 
2005-2006 
(NR) 
529 CRC IV Post‡ OM Age, prior adjuvant therapy, aspirin use, > 1 organ affected by metastatic spread, treatment arm, KRAS mutation 
status, and a KRAS*statin interaction term. 
Ng (2011)15  
USA 
Prospective cohort within 
RCT  
(Patient reported) 
1999-2001     
(Censored 2009, 
median 6.5 years) 
842 Colon III Post‡ OM Age, sex, family history of colorectal cancer, ECOG performance status (0 vs. 1-2), T stage (T1/T2 vs. T3/T4), 
number of positive lymph nodes (1-3 vs. ≥4), perineural invasion, extravascular invasion, postoperative CEA (<5 vs. 
≥5 ng/mL), treatment arm, BMI, physical activity, Western pattern diet, KRAS mutation status, and aspirin use. 
Lakha (2012)13  
Scotland 
Prospective cohort within 
case-control study  
(Dispensing database) 
1999-2006     
(Censored 2009) 
309 CRC I-IV Pre 
& 
Post§ 
CSM 
 &  
OM 
Stage, age, and sex. 
Anderson (2014)19 
USA 
Retrospective cohort  
(Medical record review) 
2005-2009  
(Censored 2013) 
230 CRC I-IV Post‡ OM¶ Age at diagnosis, stage, margin status and chemotherapy use. 
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Table 4 continued. Baseline characteristics of included studies investigating statin use and survival outcomes in colorectal cancer. 
First Author (year) 
Country 
Study design  
(Exposure Ascertainment) 
Study Period 
(Follow-up) 
No. of 
Patients 
Tumour 
Location Stage 
Statin 
Use Outcome Adjusted Variables 
Armstrong (2015)41 
Canada 
Retrospective cohort 
(Medical record review) 
2005-2012 
(Median 3.7 years) 
891 Rectum I-III Pre OM¶ Age at diagnosis, pathologic stage, performance status, sex and adjuvant chemotherapy use 
Kim (2015)42 
Korea 
Retrospective cohort 
(Medical record review) 
2007-2009 
(NR) 
 
 
239 CRC III Post¶ CSM Age, sex, comorbidity, pre-diagnosis aspirin use, medication, cancer site, initial stage and pathological 
differentiation 
Mace (2013)14 
USA 
Retrospective cohort  
(Medical record review) 
2000-2012                   
(Report 5 year 
outcomes) 
394 Rectum I-IV Post‡ CSM  
&  
OM 
Age, BMI, ASA class (III/IV vs. I/II), AJCC tumour regression grade, and stage. 
Siddiqui (2009)17  
USA 
Retrospective cohort 
(Dispensing database) 
1997-2003      
(Report 5 year 
outcomes) 
1309 CRC I-IV Pre CSM  
&  
OM 
Stage, anatomical site (right vs. other), presence of metastases, NSAIDs, and BMI for OM. 
 
Unadjusted hazard ratio for CSM estimated using Parmar’s method based on the log rank test reported in the 
manuscript. 
Abbreviations: RCT – randomised controlled trial; CRC – colorectal cancer; NR – not reported; CSM – cancer-specific mortality; OM – overall mortality; ACEIs – angiotensin converting enzyme inhibitors; BMI – body mass index; NSAIDs – non-steroidal anti-
inflammatory drugs; HRT – hormone replacement therapy; ARBs – angiotensin receptor blockers; AJCC – American Joint Committee on Cancer; ECOG – Eastern Cooperative Oncology Group; CEA – Carcinoembryonic antigen. Footnotes:  † Time-varying 
covariates of post-diagnostic statin use considered in the survival analysis; ‡ Statin use ascertained at a single time point in the early post-diagnosis period to negate the risk of immortal time bias; § Study at risk of immortal time bias as ever/never drug exposure 
was determined based on use at any time in the follow-up period but did not include a time-varying covariate; ¶ Authors provided additional information upon request. 
  
38 
 
FIGURE LEGENDS 
 
Figure 1. Flow chart of the selection of publications included in the meta-analysis. 
 
Figure 2. Forest plot of post-diagnostic statin use and (A) colorectal cancer-specific 
survival and (B) overall survival. † - Parmar method used to estimate hazard ratio 
from log rank test; ‡ - Authors contacted for additional information including adjusted 
hazard ratios. 
 
Figure 3. Forest plot of pre-diagnostic statin use and (A) colorectal cancer-specific 
survival and (B) overall survival. † - Parmar method used to estimate hazard ratio 
from log rank test; ‡ - Authors contacted for additional information including adjusted 
hazard ratios. 
 
